Observational Post-Authorisation Study of Oxervate® (Cenegermin 20 µg/ml) eye drops in the treatment of adult patients with moderate or severe Neurotrophic Keratopathy. (DEV0118) First published 15/11/2019 Last updated 23/02/2022 EU PAS number:EUPAS32335 Study Finalised